openPR Logo
Press release

Angina Pectoris Treatment Market - Global Industry Insights, 2025

02-09-2018 07:36 AM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Angina Pectoris Treatment Market - Global Industry Insights,

Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1158

Angina Pectoris Treatment Market Taxonomy

By Drug Class:

-Beta blockers
-Calcium channel blockers
-Nitrates
-Angiotensin-converting enzyme inhibitors
-Other

By Indication:

-Stable Angina
-Unstable Angina

New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market

Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.

Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi's Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/angina-pectoris-treatment-market-1158

Strategic activities by market players to increase their market share

Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.

The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angina Pectoris Treatment Market - Global Industry Insights, 2025 here

News-ID: 937751 • Views: 257

More Releases from Pharmaceutical Report By CMI

Angina Pectoris Treatment Market - Global Industry Insights 2025
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest.
Glucagon-Like Peptide-1 (Glp-1) Analogs Market - Global Industry Insights - 2025
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
U.S. Opioids Market to Surpass US$ 18,985.4 Million Threshold by 2024
Opioids Crisis – Public Health Emergency Opioids are the class of drugs that include illicit drugs such as heroin, codeine, fentanyl, meperidine, methadone, morphine, hydrocodone, diphenoxylate, hydromorphone, methylphenidate, oxycodone, and oxymorphone, which are generally prescribed for pain management. Opioids are also prescribed for treatment of cough and diarrhea. According to the survey conducted by Center for Behavioral Health Statistics and Quality (CBHSQ), in 2015, out of 20.5 million about 2 million
Rx Medical Food Market to Surpass US$ 26,455.7 Million Threshold by 2025 Globall …
Rx Medical Food – Let Medicine Be the Food Medical food is a category of products for dietary management or supportive therapy for specific disease or medical conditions such as pulmonary and metabolic disorders. Ingredients used in medical foods must have generally recognized as safe (GRAS) status, which is assigned to naturally found food materials. Medical food is different from nutritional food, dietary supplements, and prescription drugs. Medical food is protein-based,

All 5 Releases


More Releases for Angina

Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to
Refractory Angina Market accentuating the growth 2025
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Angina (Angina Pectoris) Key Players - Angionetics Inc, Hemostemix Inc, and ID P …
Angina (Angina Pectoris) Overview Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high
Angina (Angina Pectoris) Pipeline Review, H2 2017
The Report Angina (Angina Pectoris) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2017, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape. Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs
Refractory Angina Market: Industry Survey and Outlook 2025
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Latest Study Report On Refractory Angina Market : 2017
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows